LY 2087101

Potentiator of nAChRs CAS# 913186-74-0

LY 2087101

Catalog No. BCC7869----Order now to get a substantial discount!

Product Name & Size Price Stock
LY 2087101: 5mg $104 In Stock
LY 2087101: 10mg Please Inquire In Stock
LY 2087101: 20mg Please Inquire Please Inquire
LY 2087101: 50mg Please Inquire Please Inquire
LY 2087101: 100mg Please Inquire Please Inquire
LY 2087101: 200mg Please Inquire Please Inquire
LY 2087101: 500mg Please Inquire Please Inquire
LY 2087101: 1000mg Please Inquire Please Inquire
Related Products
  • T0901317

    Catalog No.:BCC1178
    CAS No.:293754-55-9
  • GW3965

    Catalog No.:BCC1612
    CAS No.:405911-09-3
  • GW3965 HCl

    Catalog No.:BCC3790
    CAS No.:405911-17-3
  • Fexaramine

    Catalog No.:BCC7412
    CAS No.:574013-66-4

Quality Control of LY 2087101

Number of papers citing our products

Chemical structure

LY 2087101

3D structure

Chemical Properties of LY 2087101

Cas No. 913186-74-0 SDF Download SDF
PubChem ID 11964458 Appearance Powder
Formula C15H11FN2OS2 M.Wt 318.39
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 100 mM in DMSO and to 10 mM in ethanol
Chemical Name [2-(4-fluoroanilino)-4-methyl-1,3-thiazol-5-yl]-thiophen-3-ylmethanone
SMILES CC1=C(SC(=N1)NC2=CC=C(C=C2)F)C(=O)C3=CSC=C3
Standard InChIKey PEAMDZVDNYENPN-UHFFFAOYSA-N
Standard InChI InChI=1S/C15H11FN2OS2/c1-9-14(13(19)10-6-7-20-8-10)21-15(17-9)18-12-4-2-11(16)3-5-12/h2-8H,1H3,(H,17,18)
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of LY 2087101

DescriptionAllosteric potentiator of α7, α4β2 and α4β4 nAChRs; displays selectivity against α3β4 nAChRs. Thought to potentiate agonist-evoked α7 responses by binding within the nAChR transmembrane region.

LY 2087101 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

LY 2087101 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of LY 2087101

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1408 mL 15.704 mL 31.408 mL 62.816 mL 78.5201 mL
5 mM 0.6282 mL 3.1408 mL 6.2816 mL 12.5632 mL 15.704 mL
10 mM 0.3141 mL 1.5704 mL 3.1408 mL 6.2816 mL 7.852 mL
50 mM 0.0628 mL 0.3141 mL 0.6282 mL 1.2563 mL 1.5704 mL
100 mM 0.0314 mL 0.157 mL 0.3141 mL 0.6282 mL 0.7852 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on LY 2087101

Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.[Pubmed:27238974]

Eur J Pharmacol. 2016 Sep 5;786:169-178.

Some drugs that are positive allosteric nAChR modulators in vitro, desformylflustrabromine (dFBr), PNU-120596 and LY 2087101, have not been fully characterized in vivo. These drugs were examined for their capacity to share or modify the hypothermic and discriminative stimulus effects of nicotine (1mg/kg s.c.) in male C57Bl/6J mice. Nicotine, dFBr, and PNU-120596 produced significant hypothermia, whereas LY 2087101 (up to 100mg/kg) did not. Nicotine dose-dependently increased nicotine-appropriate responding and decreased response rate; the respective ED50 values were 0.56mg/kg and 0.91mg/kg. The modulators produced no more than 38% nicotine-appropriate responding up to doses that disrupted operant responding. Rank order potency was the same for hypothermia and rate-decreasing effects: nicotine>dFBr>PNU-120596=LY 2087101. Mecamylamine and the alpha4beta2 nAChR antagonist dihydro-beta-erythroidine, but not the alpha7 antagonist methyllycaconitine, antagonized the hypothermic effects of nicotine. In contrast, mecamylamine did not antagonize the hypothermic effects of the modulators. The combined discriminative stimulus effects of DFBr and nicotine were synergistic, whereas the combined hypothermic effects of nicotine with either dFBr or PNU-120596 were infra-additive. PNU-120596 did not modify the nicotine discriminative stimulus, and LY 2087101 did not significantly modify either effect of nicotine. Positive modulation of nicotine at nAChRs by PNU-120596 and LY 2087101 in vitro does not appear to confer enhancement of the nAChR-mediated hypothermic or discriminative stimulus effects of nicotine. However, dFBr appears to be a positive allosteric modulator of some behavioral effects of nicotine at doses of dFBr smaller than the doses producing unwanted effects (e.g. hypothermia) through non-nAChR mechanisms.

Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators.[Pubmed:16738207]

J Pharmacol Exp Ther. 2006 Sep;318(3):1108-17.

Here we report the discovery, by high-throughput screening, of three novel (2-amino-5-keto)thiazole compounds that act as selective potentiators of nicotinic acetylcholine receptors. Compound selectivity was assessed at seven human nicotinic acetylcholine receptors (alpha1beta1gammadelta, alpha2beta4, alpha3beta2, alpha3beta4, alpha4beta2, alpha4beta4, and alpha7) expressed in mammalian cells or Xenopus oocytes. At alpha2beta4, alpha4beta2, alpha4beta4, and alpha7, but not alpha1beta1gammadelta, alpha3beta2, or alpha3beta4, submaximal responses to nicotinic agonists were potentiated in a concentration-dependent manner by all compounds. At similar concentrations, no potentiation of 5-hydroxytryptamine, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, GABA(A), and N-methyl-d-aspartate receptors or voltage-gated Na(+) and Ca(2+) channels was observed. Furthermore, these compounds did not inhibit acetylcholine esterase. Further profiling revealed that these compounds enhanced the potency and maximal efficacy of a range of nicotinic agonists at alpha4beta2 nicotinic acetylcholine receptors, a profile typical of allosteric potentiators. At concentrations required for potentiation, the compounds did not displace [(3)H]epibatidine from the agonist-binding site, and potentiation was observed at all agonist concentrations, suggesting a noncompetitive mechanism of action. Blockade of common second messenger systems did not affect potentiation. At concentrations higher then required for potentiation the compounds also displayed intrinsic agonist activity, which was blocked by competitive and noncompetitive nicotinic acetylcholine receptor (nAChR) antagonists. These novel selective nicotinic receptor potentiators should help in clarifying the potential therapeutic utility of selective nAChR modulation for the treatment of central nervous system disorders.

Keywords:

LY 2087101,913186-74-0,Natural Products,Nicotinic Receptor, buy LY 2087101 , LY 2087101 supplier , purchase LY 2087101 , LY 2087101 cost , LY 2087101 manufacturer , order LY 2087101 , high purity LY 2087101

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: